CCB vs. ARB: Which Has Better Cardiovascular Outcomes?

the MPR take:

Are calcium channel blockers (CCB) superior to angiotensin II receptor blockers (ARB) for reducing the risk of cardiovascular events and mortality? A review of eight head-to-head trials of 25,084 patients and CCB vs. ARB found no significant difference in heart failure (HF) incidence and mortality between the two therapies, although there was a lower trend in HF incidence in the ARB group. CCBs were more effective in stroke reduction and myocardial infarction incidence, leading the authors to suggest that their initial use may be superior to ARB for stroke and MI prevention.

Abstract: To explore the clinical effects of a calcium channel blocker compared with an angiotensin II receptor blocker in hypertensive patients, the authors collected data from randomized controlled trials. The pooled outcomes were all-cause mortality, stroke, myocardial infarction, and heart failure.